Baseline characteristics of the 14 patients
| Patient | Age | Sex | MS duration (years) | Relapses* | EDSS | AI | SNRS | Previous treatment |
|---|---|---|---|---|---|---|---|---|
| The duration of MS was counted from the second demyelinating event, usually time of diagnosis. | ||||||||
| *Total number in the preceding year. | ||||||||
| AI, ambulation index; INFβ, interferon β1a or β1b; IVIG, intravenous immunoglobulin; MP, methylprednisolone; MS, multiple sclerosis; SNRS, Scripps neurological rating scale. | ||||||||
| 1 | 31 | M | 5 | 2 | 6 | 4 | 67 | IFNβ |
| 2 | 39 | M | 4 | 1 | 6.5 | 5 | 59 | – |
| 3 | 48 | F | 5 | 1 | 6.5 | 6 | 55 | – |
| 4 | 47 | M | 5 | 0 | 6.5 | 4 | 56 | – |
| 5 | 44 | F | 4 | 5 | 6.5 | 6 | 66 | IFNβ |
| 6 | 31 | F | 5 | 3 | 5.5 | 4 | 62 | IFNβ |
| 7 | 37 | F | 5 | 0 | 6 | 4 | 67 | – |
| 8 | 50 | F | 4 | 0 | 5.5 | 3 | 77 | – |
| 9 | 41 | F | 2 | 1 | 6 | 6 | 76 | IFNβ + IVIG |
| 10 | 23 | M | 6 | 2 | 6 | 5 | 64 | IFNβ + IVIG |
| 11 | 34 | F | 3 | 1 | 5 | 3 | 66 | IFNβ |
| 12 | 34 | M | 12 | 1 | 6 | 4 | 51 | IFNβ |
| 13 | 32 | M | 8 | 2 | 6 | 4 | 76 | IFNβ |
| 14 | 35 | F | 6 | 0 | 6.5 | 6 | 67 | IFNβ |